| It should follow the same precautions with other benzodiazepines which are metabolized by CYP3A, including triazolam and alprazolam. For benzodiazepines, the elimination of which is not dependent on CYP3A (temazepam, nitrazepam, lorazepam), development of clinically significant interaction with clarithromycin is unlikely.
Clarithromycin buy
There are post-marketing reports of drug interactions and side effects of the development of the central nervous system (such as drowsiness and confusion) with the combined use of clarithromycin and tryazolamu. It is necessary to observe the patient, taking into account the possible increase of pharmacological effects of the central nervous system.
Other interactions Colchicine
Colchicine is a substrate of CYP3A and P-glycoprotein (Pgp). It is known that clarithromycin and other macrolides can inhibit CYP3A and Pgp. Concomitant administration of clarithromycin and colchicine inhibition of CYP3A and Pgp clarithromycin may lead to increased exposure colchicine. It is necessary to observe the condition of the patients to detect clinical symptoms of colchicine toxicity. The dose of colchicine should be reduced while the use of clarithromycin in patients with normal renal and hepatic function. Concomitant administration of clarithromycin colchicine in patients with renal or hepatic impairment is contraindicated (see. Sections "Contraindications", "Peculiarities of Application").Clarithromycin buy
Digoxin
Digoxin is considered substrate P-glycoprotein (Pgp). It is known that clarithromycin is able to inhibit Pgp. In an application Pgp inhibition may lead to increased exposure of digoxin. During postmarketing surveillance reports of increased concentrations of digoxin in the serum of patients who used clarithromycin with digoxin.Clarithromycin buy
Some patients developed signs dyhitalisnoyi toxicity, including potentially fatal arrhythmias. It is necessary to carefully monitor the concentration of digoxin in the serum of patients when used with clarithromycin.
|